ANO1 and Familial prostate cancer: Taken together, these results highlight TMEM16A not only as a potential biomarker for prostate cancer but also as a promising target for therapeutic strategies, setting the stage for the advancement of targeted treatments that may greatly influence patient management and outcomes.